Korro Bio, Inc.
KRROHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeKorro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent. With a market capitalization of $180.2M, it sits in micro-cap territory. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Market Cap
$180.2M
Beta
2.25
P/E (TTM)
—
P/E (Fwd)
-2.75
EPS (TTM)
$-9.89
EPS (Fwd)
$-4.46
ROE
-97.7%
ROA
-28.0%
Cash
$115.0M
Total Debt
$42.2M
Free CF
-$41.4M
52W Change
-66.1%
Annual Financials
Cash vs Debt
Where KRRO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KRRO finished 2.52% below its 150-day moving average ($12.28) and 7.07% above its 200-day moving average ($11.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KRRO overbought or oversold?
At the September 3, 2026 close, KRRO's RSI(14) was 36.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $115.0M in cash comfortably exceeding the $42.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$41.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -97.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, KRRO tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, KRRO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Korro Bio, Inc.'s trajectory.